Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus gemcitabine + docetaxel vs gemcitabine + docetaxel in pediatric and young adult relapsed/recurrent/refractory synovial sarcoma
2018-004243-23Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ramucirumab in synovial sarcoma (SS) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: progression-free survival. Started Apr 2019; status: completed.
02
Drugs
ramucirumab
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on 2018-004243-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004243-23.